Background Gastroenterologists are often hampered by the lack of a reliable, non-invasive index of bowel inflammation when establishing a differential diagnosis for patients presenting with chronic diarrhoea. Investigations aim to distinguish between inflammatory bowel disease (IBD) (e.g. Crohn's disease, ulcerative colitis) and irritable bowel syndrome (IBS). As an acute phase protein, faecal calprotectin measurement may be useful in this context.
Introduction
The diagnosis and management of patients presenting to gastroenterologists with chronic diarrhoea is hampered by the lack of a reliable, speci¢c, noninvasive index of bowel in£ammation. 1 Calprotectin is now emerging as a new faecal marker that may solve this problem. 1^5 It is an acute phase protein and is the major protein of the neutrophil cytosol. When measured in faeces, it can therefore provide a direct index of neutrophil recruitment into the bowel and hence may be a speci¢c marker of bowel in£ammation.
In this study, we evaluated a new enzyme-linked immunosorbent assay (ELISA)-based assay for the measurement of calprotectin and carried out a retrospective assessment of the ability of calprotectin to distinguish between patients with Crohn's disease and irritable bowel syndrome (IBS), in the setting of a routine gastroenterology clinic.
Methods

Study design
Random stool samples were collected from patients attending the gastroenterology clinic, with a diagnosis of either IBS or Crohn's disease. All patients with IBS (4 men, 21 women; age range 25^69 years, median 41 years) had been diagnosed within the previous year of providing a specimen and were symptomatic at the time of sampling (positive Rome II criteria). 6 Other gastrointestinal pathology had been excluded by barium radiology, blood tests and intestinal biopsy. All Crohn's disease patients (7 men, 18 women; age range 31^60 years, median 36 years) had active disease (based on a Crohn's disease activity index of 4150) 7 and had a proven histological diagnosis. Control samples (9 men, 18 women, age range 31^60 years, median 42 years) were collected from healthy volunteers (no symptoms of bowel disease, no previous bowel resection and no medication). Patients with any of the following were excluded from the study: diagnosed malignancy; anti-in£ammatory medication or steroids for any indication other than Crohn's disease; known large bowel disease; younger than 18 years old; or cardiac, hepatic, or renal impairment.
All samples were posted to the laboratory and stored at 770 o C. The Bro Taf Local Research Ethics Committee approved the study and all volunteers gave written informed consent prior to sample collection. 
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Assay characterization
Inter-and intra-batch imprecision were determined using quality control material prepared in-house from stool samples with appropriate concentrations of calprotectin. Due to volume limitations, separate material was used for each type of imprecision.
The detection limit was determined from multiple determinations of the zero standard. 8
Sample analysis
All analyses were carried out by Health Professions Council (HPC)-registered sta¡, who were blinded to clinical details of the patients, in a Chemical Pathology Accreditation (CPA)-accredited laboratory. Calprotectin was measured by an ELISA-based method (Calprotech Ltd, London, UK) and all reagents were supplied with the kit.
Sample extraction
A known weight of stool (between 40 and120 mg) was diluted 1 in 50 weight for volume with extraction bu¡er. After vortex mixing, samples were homogenized on a roller mix for 25 min. The homogenate (1 mL) was centrifuged for 20 min at 10 000 g and 0.5 mL of the supernatant stored at 7708C until use.
Assay
All supernatants from extracted samples were diluted 1 in 50 with dilution bu¡er. Diluted supernatants, controls and standards were added to duplicate wells of a 96-well plate. The plate was covered and incubated at room temperature for 45 min prior to washing. Alkaline-phosphatase-labelled anti-calprotectin antibody conjugate (100 mL) was added to each well, and after a further incubation a second washing step was performed. The p-nitrophenylphosphate substrate (100 mL) was then added and the plate read at 405 nm (Anthos HTIII plate reader, Anthos UK Ltd, Essex, UK) after a 30-min incubation in the dark.
Calprotectin concentration was calculated using Biolise software (version 1.65, 1994 Life Sciences International Cergy-Pontoise France) and expressed as mg of calprotectin per g of stool. 
Statistical analysis
Results
There were no signi¢cant di¡erences in age or gender between the di¡erent groups, although more women than men were included in each group.
Intra-batch imprecision was1.4% (15.2 mg/g, nˆ10) and 4.5% (63.5 mg/g, nˆ10); inter-batch imprecision was 21.2% (24.4 mg/g, nˆ15) and 11.2% (58.5 mg/g, nˆ17). The lower limit of detection of the assay was de¢ned as the mean of the zero standard plus three times the standard deviation of repeat measures 8 (nˆ17) and gave a value of 6.5 mg/g.
The concentrations of calprotectin in the di¡erent patient groups are shown in Table 1 .
Patients with Crohn's disease had signi¢cantly greater concentrations of calprotectin than did either IBS patients or controls (P50.001) (see Fig. 1 ). There was no signi¢cant di¡erence between the IBS group and controls (Pˆ0.06).
All controls and patients with IBS had calprotectin concentrations of less than 90 mg per g of stool. In the Crohn's disease group, 21/25 patients had concentrations in excess of this value.
Discussion
Results for intra-batch imprecision compared well with those previously reported: 1.9% (concentration of calprotectin unstated) 9 and 3.1% (20 mg/g) 3 . Interassay imprecision was not as good as that reported by Carroccia et al. (10% at 21 mg/g) 3 . This may re£ect variation in the number of di¡erent kit lot numbers used in the two studies or in the time over which each study was performed.We found a lower detection limit than that quoted by the manufacturers (manufacturer's value 15.6 mg/g). Direct comparisons are however di¤cult as no information was given about how detection limit was determined.
This study con¢rms the ¢nding of previous investigations that a single faecal calprotectin measurement can aid gastroenterologists in the di¡erential diagnosis of Crohn's disease and IBS. 3, 4 Although our study used relatively small numbers of patients, an optimum cut-o¡ and sensitivity/speci-¢city of calprotectin for the diagnosis of Crohn's disease was determined. A wide range of optimum cut-o¡s have been reported when using a calprotectin measurement to distinguish between patients with Crohn's disease, in£ammatory bowel disease and IBS. 1^5 Our retrospective study found that at 90 mg calprotectin per g of stool, calprotectin gave a sensitivity/speci¢city of 85%/100% to distinguish between Crohn's disease and IBS. Carroccio et al. (2003) 3 reported a sensitivity and speci¢city of100% and 95%, respectively (170 mg/g cut-o¡ ), but used only 10 patients. In a larger prospective study (31 patients with Crohn's disease, 159 with IBS), 2 found that at a cut-o¡ of 30 mg/g, calprotectin had 100% sensitivity and 97% speci¢city. This variation in optimum cut-o¡s may re£ect di¡erences in study design and in characteristics of patients included in the study.
Conclusion
A single calprotectin measurement may aid gastroenterologists in the di¡erential diagnosis of Crohn's disease and IBS. Its use could decrease the number of invasive and radiological investigations undertaken in the latter group of patients. 
